New Article on AGN From MedicalGold As $AGN.C continues to progress with their research and development, a new article from MedicalGold highlights the numerous bullish fundamentals behind $AGN.C’s strategy.
Their focus on drug repurposing has 3 main advantages, lower risk of failure, shortened timeline due to completed safety trials, and fewer research costs/it is far more cost-effective. Their Drug Development Programs include Ifenprodil, reprinast, and DMT for novel uses to treat things such as IPF, ischemic stroke, or chronic cough. And with the phase 2a trials for Ifenprodil to treat IPF/chronic cough having shown statistical significance on improved conditions, Ifenprofil’s potential as a treatment has only continued to rise. The Phase 2b study for Ifenprodil will also have multiple arms, multiple doses, will be placebo-controlled and will be double-blinded and randomized. Furthermore, the phase 1 DMT study will determine the safety, tolerability, pharmacokinetics, and to confirm pre-clinical research of their proprietary DMT salt formulation when administered. It will set the stage for future research potential with the formulation. Now, moving into the future, the article has highlighted numerous catalysts to look out for.
- Continued research trials: Phase 2b Ifenprodil, phase 1 DMT, and other related trials.
- The complete dataset from its Phase 2a Study of Ifenprodil for IPF and chronic cough.
- File an application with the U.S. FDA for a Breakthrough Therapy designation as soon as possible.
Check it out here: https://www.medicalgold.ca/featured/algernon-human-clinical-trials-update
Considering that the stock has rallied over 30% in the last month, the market has begun to take notice of the recent developments and potential for the company. Only an $8.2M market cap at these levels, so definitely keep a close eye out for any future news.